hero section gradient
15 handpicked stocks

Employee Mental Health As A Benefit

Discover companies transforming workplace wellness through innovative mental health solutions. These carefully selected stocks represent businesses helping corporations attract and retain talent by offering digital therapy, virtual counseling, and wellness technologies as employee benefits.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Market capitalisation breakdown for the 'Employee Mental Health As A Benefit' basket.

Key Takeaways for Investors:
  • Large-cap concentration tends to lower volatility and produces more market-like, less idiosyncratic performance.
  • Use this basket as a core holding for diversified exposure, not as a speculative, high-conviction trade.
  • Expect steady, long-term value-oriented growth rather than rapid, short-term explosive gains.
Total Market Cap
  • TDOC: $1.53B

  • AMWL: $90.45M

  • HIMS: $11.16B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Modern companies now see mental health support as essential for productivity and talent retention. This portfolio captures the intersection of healthcare, technology, and human resources, focusing on businesses that package psychological wellbeing services as corporate benefits.

2

What You Need to Know

This group spans telehealth providers, digital therapeutics developers, and health insurers pioneering accessible mental wellness solutions. As workplace mental health becomes a priority, these companies are positioned to benefit from growing corporate investment in employee wellbeing.

3

Why These Stocks

These companies were selected for their innovative approaches to scalable mental health solutions designed specifically for workplace implementation. Each represents a different aspect of the mental wellness ecosystem, from virtual therapy platforms to next-generation therapeutic technologies.

Why You'll Want to Watch These Stocks

🌱

The Wellness Revolution

Companies are rapidly expanding mental health benefits as the competition for talent intensifies. This shift creates substantial growth opportunities for providers in this emerging space.

💼

The New Workplace Essential

Mental wellness is no longer a luxury perk but a core benefit. Companies offering these solutions are becoming indispensable partners for modern HR departments seeking to support their workforce.

🔬

Next-Gen Treatments Emerging

Several companies in this group are pioneering innovative therapies that could transform mental healthcare. Early investors could benefit as these breakthrough approaches gain mainstream acceptance in workplace benefits.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions